Kmieciak M - Search Results

1

Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.

Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, Leverson JD, Sampath D, Ferreira-Gonzalez A, Grant S. Rahmani M, et al. Among authors: kmieciak m. Cancer Res. 2018 Jun 1;78(11):3075-3086. doi: 10.1158/0008-5472.CAN-17-3024. Epub 2018 Mar 20. Cancer Res. 2018. PMID: 29559471 Free PMC article.

2

Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM, Manjili MH. Worschech A, et al. Among authors: kmieciak m. Cancer Res. 2008 Apr 1;68(7):2436-46. doi: 10.1158/0008-5472.CAN-07-6822. Cancer Res. 2008. PMID: 18381452 Free PMC article.

3

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.

Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. Morales JK, et al. Among authors: kmieciak m. Breast Cancer Res Treat. 2010 Aug;123(1):39-49. doi: 10.1007/s10549-009-0622-8. Epub 2009 Nov 8. Breast Cancer Res Treat. 2010. PMID: 19898981 Free PMC article.

4

The role of Tyk2 in regulation of breast cancer growth.

Zhang Q, Sturgill JL, Kmieciak M, Szczepanek K, Derecka M, Koebel C, Graham LJ, Dai Y, Chen S, Grant S, Cichy J, Shimoda K, Gamero A, Manjili M, Bear H, Conrad D, Larner AC. Zhang Q, et al. Among authors: kmieciak m. J Interferon Cytokine Res. 2011 Sep;31(9):671-7. doi: 10.1089/jir.2011.0023. Epub 2011 Aug 24. J Interferon Cytokine Res. 2011. PMID: 21864028 Free PMC article.

5

A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.

Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S. Holkova B, et al. Among authors: kmieciak m. Clin Cancer Res. 2013 Apr 1;19(7):1873-83. doi: 10.1158/1078-0432.CCR-12-2926. Epub 2013 Mar 20. Clin Cancer Res. 2013. PMID: 23515411 Free PMC article. Clinical Trial.

6

The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

Dai Y, Chen S, Kmieciak M, Zhou L, Lin H, Pei XY, Grant S. Dai Y, et al. Among authors: kmieciak m. Mol Cancer Ther. 2013 Jun;12(6):878-89. doi: 10.1158/1535-7163.MCT-12-0902. Epub 2013 Mar 27. Mol Cancer Ther. 2013. PMID: 23536721 Free PMC article.

7

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.

Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S. Chen S, et al. Among authors: kmieciak m. Blood. 2014 Oct 23;124(17):2687-97. doi: 10.1182/blood-2014-03-564534. Epub 2014 Sep 10. Blood. 2014. PMID: 25208888 Free PMC article.

8

Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.

Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Holkova B, et al. Among authors: kmieciak m. Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23. Clin Cancer Res. 2014. PMID: 25248382 Free PMC article. Clinical Trial.

9

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.

Zhou L, Zhang Y, Chen S, Kmieciak M, Leng Y, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Dai Y, Grant S. Zhou L, et al. Among authors: kmieciak m. Leukemia. 2015 Apr;29(4):807-18. doi: 10.1038/leu.2014.296. Epub 2014 Oct 6. Leukemia. 2015. PMID: 25283841 Free PMC article.

10

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S. Nguyen T, et al. Among authors: kmieciak m. Leuk Res. 2015 Jan;39(1):65-71. doi: 10.1016/j.leukres.2014.10.009. Epub 2014 Nov 11. Leuk Res. 2015. PMID: 25465126 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page